| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.05. | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year | 266 | Business Wire | Regulatory filings planned for US, EU, UK and Japan to enable multiple 2025 commercial launches -
Development strategy refined for oral Factor XIIa program -
Organizational focus to drive results... ► Artikel lesen | |
| 22.04. | KalVista Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.04. | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors | 136 | Business Wire | KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today... ► Artikel lesen | |
| 02.04. | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 214 | Business Wire | KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted nine newly-hired employees inducement options to purchase an... ► Artikel lesen | |
| 18.03. | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas | 241 | Business Wire | Delays in treating attacks lead to increased anxiety, quality of life issues, higher frequency of returning attacks, and suboptimal clinical outcomes in both on-demand and prophylaxis patients -
KalVista... ► Artikel lesen | |
| 12.03. | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat | 264 | Business Wire | - Full EAMS designation would allow treatment of patients with sebetralstat prior to receiving a Marketing Authorization from UK
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical... ► Artikel lesen | |
| 11.03. | KalVista Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 11.03. | Kalvista Pharmaceuticals Inc reports results for the quarter ended in January - Earnings Summary | - | Reuters | ||
| 11.03. | Recap: KalVista Pharma Q3 Earnings | 1 | Benzinga.com | ||
| 11.03. | KalVista Pharmaceuticals GAAP EPS of -$0.84 misses by $0.07 | 1 | Seeking Alpha | ||
| 11.03. | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update | 286 | Business Wire | Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety profile as first oral on-demand therapy for hereditary angioedema -
CEO transition supports ongoing... ► Artikel lesen | |
| 11.03. | KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update | 69 | Business Wire | CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization... ► Artikel lesen | |
| 08.03. | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas | 440 | Business Wire | KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today... ► Artikel lesen | |
| 07.03. | KalVista appoints new CEO amid shift to commercial stage | 2 | Investing.com | ||
| 07.03. | KalVista Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.03. | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer | 207 | Business Wire | Planned transition reflects evolution to commercial company with sebetralstat for HAE -
NDA filing remains on track for H1 2024; Europe and Japan filings H2 2024
KalVista Pharmaceuticals, Inc.... ► Artikel lesen | |
| 06.03. | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference | 206 | Business Wire | KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today... ► Artikel lesen | |
| 04.03. | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 190 | Business Wire | KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted seven newly-hired employees inducement options to purchase an... ► Artikel lesen | |
| 27.02. | KalVista presents HAE patient challenges at AAAAI | 1 | Investing.com | ||
| 27.02. | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting | 281 | Business Wire | Patient perspectives revealed frequent treatment delays, suboptimal clinical outcomes and substantial anxiety associated with injectable on-demand treatments, including those who received long-term... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 3.081 |
| EVOTEC | 2.435 |
| TUI | 1.927 |
| NEL | 1.230 |
| PLUG POWER | 1.048 |
| BAYER | 1.038 |
| NVIDIA | 1.022 |
| AMC ENTERTAINMENT | 989 |
| RHEINMETALL | 977 |
| SIEMENS ENERGY | 858 |
| DEUTSCHE BANK | 836 |
| RENK GROUP | 813 |
| REDCARE PHARMACY | 679 |
| COMMERZBANK | 657 |
| HEIDELBERGER DRUCK | 651 |
| ALIBABA | 645 |
| VOLKSWAGEN | 610 |
| E.ON | 565 |
| BARRICK GOLD | 538 |
| BYD | 534 |
| SIEMENS | 519 |
| RWE | 514 |
| AIXTRON SE | 507 |
| SFC ENERGY | 505 |
| TESLA | 505 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
